Ersin Erfa – CEO, Centurion

21.09.2021
Ersin Erfa, CEO of Centurion, a Turkish manufacturer, discusses the company’s high ambitions, R&D capabilities, and their work on a COVID-19 treatment currently in phase II clinical trials. Erfa explains how their work on orphan drugs, innovative generics, vaccines and plasma will help them continue partnering with global companies to expand their geographical reach.  
We are not interested in mass production products, rather focusing on niche generics where there are far more opportunities worldwide
Become a PharmaBoardroom Member for free to access this content
Join the 20,000+ pharmaceutical professionals who already subscribe to PharmaBoardroom
Register
Already a member? Sign In
Tags:
Turkey, Centurion, Generics, Vaccines, Plasma

Related Interviews

Demet Eryilmaz – General Manager Turkey, Queisser

Queisser Pharma is a German company focused on the OTC market through food supplements and medical devices. Its general manager for Turkey, Demet Eryilmaz, tells the “special” story of its…

Umut Ağyüz – Founder & CEO, Genz Biotechnology

Genz Biotechnology is a biotech startup working on novel diagnostic testing solutions. Its founder and CEO, Umut Ağyüz, explains the origins of the company, the big opportunities that have arisen…

Souheil A ElHakim – CEO, Bıçakcılar

Bıçakcılar is one of Turkey’s largest medical technology companies, selling disposables and focusing on the operating room, any hospital’s most profitable part. Souheil A. ElHakim, the company’s CEO, reflects on…

Related Articles

Turkey / Biosimilars on the Rise

With an already well-established manufacturing industry for pharmaceuticals, Turkey has been aiming to move with global trends and invest in biologics production, specifically in biosimilars.   The share of biotechnological…

Turkey / Can It Become a True Clinical Trials Hub?

Becoming the clinical trials country leader in the region has been set as a primary goal for Turkey’s pharma industry to achieve global competitiveness. The government’s strategy is to increase…

Turkey / GEN: From Niche Distributor to Public Company

Few Turkish companies are experiencing such a transformational moment as GEN. In 2021 alone, the Ankara-based organization made its public debut on the Istanbul Stock Exchange and signed an exclusive…

Latest Report

Denmark Pharma Report 2021

Related Content

Turkey
Centurion
Generics
Vaccines
Plasma